N
PLRX icon

Natixis’s Pliant Therapeutics PLRX Stock Holding History

Natixis’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-55,000
Closed -$617K – 1160
2024
Q3 		$617K Buy
+55,000
New +$688K ﹤0.01% 607
2023
Q1 		– Sell
-98,600
Closed -$1.91M – 1150
2022
Q4 		$1.91M Buy
+98,600
New +$2.06M 0.01% 543

Other funds holding PLRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Natixis's PLRX Position: Q4 2024 in Review

Natixis sold out of Pliant Therapeutics (PLRX) in Q4 2024, closing a stake of 55,000 shares — an estimated $617K sold.

Natixis first reported a position in PLRX in Q4 2022 and held it in 2 quarters. The position peaked at $1.91M in Q4 2022. 160 funds tracked by Wall St. Rank hold PLRX as of Q4 2024.

  • Natixis reported no remaining Pliant Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Natixis sold 55,000 Pliant Therapeutics shares in Q4 2024, an estimated $617K.
  • Natixis first reported a position in Pliant Therapeutics in Q4 2022 and held it in 2 quarters.
  • Natixis's Pliant Therapeutics position peaked at $1.91M in Q4 2022.
  • 160 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q4 2024.

Based on Natixis's 13F filing for Q4 2024, filed 13 Feb 2025.